SCHEMBL20128936

SCHEMBL20128936

Cn1c2ccncc2c2ccc(-c3ccc(CCCOCCOCCOCCOCCO)nc3)cc21

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
DDB1 Q16531 2/20 0.33
CRBN Q96SW2 2/20 0.33
MAOA P21397 5/20 0.32
MAOB P27338 5/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PDE10A Q9Y233 3/20 0.32
ACHE P22303 1/20 0.31
MAPT P10636 1/20 0.31
GRIN1 Q05586 2/20 0.31
GRIN2B Q13224 2/20 0.31
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20423270 0.85 PIK3CA (0.38) NPC1POLBGAARAB9ARXFP1
SCHEMBL20129094 0.85 PIK3CA (0.38) NPC1POLBGAARAB9ARXFP1
SCHEMBL30479974 0.85 PIK3CA (0.38) NPC1POLBGAARAB9ARXFP1
SCHEMBL20129067 0.82 METAP2 (0.37) NPC1POLBGAARAB9ARXFP1
SCHEMBL20129113 0.81 GRIN2B (0.35) NPC1POLBGAARAB9ARXFP1
SCHEMBL20128973 0.81 METAP2 (0.37) NPC1POLBGAARAB9ARXFP1
SCHEMBL27097805 0.81 METAP2 (0.37) NPC1POLBGAARAB9ARXFP1
SCHEMBL20129110 0.81 GRIN1 (0.38) PDE10AMAPTGRIN1GRIN2B
SCHEMBL27098509 0.81 MAPT (0.34) NPC1POLBGAARAB9ARXFP1
SCHEMBL20128935 0.80 NPC1 (0.32) NPC1POLBGAARAB9ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN NPC1 2550/4885POLB 2944/4885GAA 926/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 NPC1 3216/4885POLB 3366/4885GAA 1764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.